Table 2.
Summary of putative markers of cardiac toxicity associated with cancer treatment.
| Reference | Tumor Type | Treatment | Detection Time Post-Treatment | Tn | BNP | NT pro-BNP | CKMB | Gal-3 | MPO | PIGF | GDF-15 | c-miRNA | CRP | s-Flt1 | H-FABP | GPBB | Notes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (155) | Breast Cancer | Chemotherapy | 3 months | ↑ | – | n.d. | – | n.d. | ↑ | ↑ | ↑ | – | ↑ | ↑ | – | – | Only TnI and MPO correlated with cardiotoxicity risk. |
| (156) | Breast Cancer | Trastuzumab | 3 month intervals | – | – | – | – | – | – | – | – | – | ↑ | – | – | – | Maximum CRP correlates with toxicity |
| (157) | Lymphoma | Chemotherapy | 24 hours after 1st dose (H-FABP) and after last dose (BNP) | – | ↑ | – | – | – | – | – | – | – | – | – | ↑ | – | Early H-FABP correlated with late BNP and reduced ejection fraction. |
| (163) | Leukemia/ Lymphoma |
Chemotherapy | n.d. | – | – | n.d. | – | – | – | – | – | – | – | n.d. | ↑ | GPBB increase correlated with LV diastolic dysfunction. |
CRP, C-reactive protein; sFlt-1, soluble fms-like tyrosine kinase receptor-1; GPBB.
-, not assessed; ↑, increased levels.